NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Epirium Bio

Epirium Bio

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://epirium.com/

Last Round

Series B

Jul 25, 2025

Total Funding Raised

$85M

Company Overview

Epirium Bio is a biopharmaceutical company that develops therapeutic drugs aimed at treating diseases associated with mitochondrial depletion and dysfunction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule inhibitors15-PGDHdrug discoveryclinical-stage biotechneuromuscular diseaseinflammatory diseaseBecker Muscular Dystrophytissue regenerationclinical trialsbiotech pipelinedrug developmentmetabolic functionpreclinical researchtherapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epirium Bio Comparables

Compare Epirium Bio with similar companies based on industry and business-model similarity.

Epirium Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NMD Pharma
76%
Rejuvenate Biomed
75%
ImmunoForge Co., Ltd.
75%

Epirium Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 25, 2025
Series ADec 18, 2019

Key People

Founding team and executive leadership

Alexander Casdin

Chief Executive Officer, Chief Executive Officer

Executive Team

Eric Miller

Chief Financial Officer

Executive Team

Epirium Bio Investors

Notable investors and investment history

Epirium Bio investors
InvestorRounds
Longitude CapitalSeries A
Vertex Ventures HCSeries A
ARCH Venture PartnersSeries A
ARCH Venture PartnersSeries A
Bluebird VenturesSeries A
The Longevity FundSeries A
Adams Street PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 30% MoM, reaching 4.6K.

  • Mar 13, 2025

    Presented preclinical data on drug candidate MF-300 at an international conference.

Epirium Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Epirium Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Epirium Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range13
Year Founded2008
Last FundingJul 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.